Europe Viscosupplementation Market, By Type (Single Injection, Cycle Three Injection Cycle, Five Injection Cycle), By End User (Hospitals, ASCs, Clinics), By Country (Western Europe (Germany, UK, France, Italy, Spain, Nordic Countries, Rest of Western Europe), Eastern Europe (Russia, Rest of Eastern Europe))-

Published In : Jul 2023

Code : CMI3891

Pages :163

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Europe Viscosupplementation Market: Key Developments

In May 2022, United Rheumatology, the rheumatology care management organization empowering rheumatologists to advance the standard of care, and CreakyJoints, a support, education, advocacy, and research organization for people living with arthritis and rheumatic disease, announced a partnership to develop the Rheumatoid Arthritis Wellness Center, a digital resource, aimed at aiding those living with rheumatoid arthritis.

In March 2022, Sanofi S.A., a multinational pharmaceutical and healthcare company headquartered in Paris, France, and IGM Bioscience, an antibody medicine for the treatment of osteoarthritis (OA) of the knee, autoimmune and inflammatory diseases, and infectious diseases, announced the signing of an exclusive worldwide collaboration agreement to create, develop, manufacture, and commercialize IgM antibody agonists against three oncology targets and three immunology/inflammation targets. IgM antibodies represent a new class of potential therapeutics that combine the multi-valency of IgM antibodies possessing 10 binding sites compared to conventional IgG antibodies having only 2 target binding sites.

In October 2022, Anika Therapeutics, Inc., an integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, announced Health Canada approval of CINGAL as a medical device to treat pain associated with osteoarthritis (OA) of the knee. CINGAL is the first and only approved combination viscosupplement formulated with the Company's proprietary cross-linked sodium hyaluronate (currently marketed as the single-injection viscosupplement MONOVISC) and triamcinolone hexacetonide, an FDA-approved steroid to treat inflammation.

In August 2021, Seikagaku Corporation, which makes and sells pharmaceuticals and medical devices related to glycoconjugates, announced the launch of HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp. HyLink is an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis whose main ingredient is a cross-linked hyaluronate hydrogel made using Seikagaku’s unique crosslinking technology.